BridgeBio Pharma, Inc. filings document a commercial-stage biopharmaceutical company focused on medicines for genetic conditions, including financial results, product revenue disclosures, program updates, and formal reports on ATTR-CM, LGMD2I/R9, and achondroplasia development programs.
Its SEC record includes Form 8-K disclosures for results of operations, Regulation FD presentations, clinical and regulatory press releases, material agreements, an at-the-market equity distribution agreement, convertible senior notes, and a board-authorized stock repurchase program. Proxy materials address director elections, executive compensation votes, auditor ratification, incentive plan share reserves, governance structure, and stockholder voting matters.
BridgeBio Pharma (NASDAQ: BBIO) filed a Form 4 disclosing that director Frank P. McCormick sold 100,000 common shares on 06/24/2025 under a pre-arranged Rule 10b5-1 plan.
The shares were sold at a weighted-average price of $44.23, generating proceeds of roughly $4.4 million.
Following the sale, McCormick owns 879,979 shares indirectly through his revocable trust and 83,275 shares directly, implying the transaction reduced his total position by about 9-10%.
No derivative securities were involved and no other insiders were party to the filing.
BridgeBio Pharma Form 144 Notice filed on June 28, 2025, details a proposed sale of securities by Denis Von Kaeppler IRA Rollover, who is related to the company through their wife's Board of Directors position.
Key transaction details:
- Securities to be sold: 1,891 shares of common stock
- Aggregate market value: $83,261.30
- Planned sale date: June 26, 2025 on NASDAQ
- Broker: Morgan Stanley Smith Barney LLC
The shares were originally acquired through an open market purchase on December 28, 2021. Notable recent insider activity includes multiple sales by Hannah Valantine, who sold a total of 17,168 shares for approximately $686,334 in gross proceeds on June 10, 2025. The company has approximately 189.9 million shares outstanding.